Lectu re - UniversitätsSpital Zürich
Transcription
Lectu re - UniversitätsSpital Zürich
Lecture Cancer Center Zürich Dienstag, 21. Juni 2016, 12.30–13.30 Uhr Hörsaal WEST, UniversitätsSpital Zürich, Rämistrasse 100, 8091 Zürich Snack ab 12.00 Uhr Current treatment paradigms in advanced prostate cancer Joe O’Sullivan Queen’s University Belfast, and the Northern Ireland Cancer Centre, Belfast, Northern Ireland Joe O’Sullivan graduated from the University College Dublin Medical School in 1993. After specialist training in Dublin, he became a clinical research fellow at The Academic Urology Unit of the Royal Marsden Hospital, where he completed an MD on the subject of bone seeking radionuclide therapy in metastatic castration-resistant prostate cancer. In 2004, Professor O’Sullivan was appointed Senior Lecturer and Consultant in Clinical Oncology at The Centre for Cancer Research and Cell Biology at Queen’s University Belfast, and the Northern Ireland Cancer Centre, Belfast. He was appointed Professor of Radiation Oncology at Queen’s University Belfast in October 2011, and became the Clinical Director of Oncology at the Belfast Health and Social Care Trust in September 2014. Professor O’Sullivan leads the radiation oncology and prostate cancer clinical research groups at the Northern Ireland Cancer Centre and is currently principal investigator on more than 10 clinical trials. His research interests include castration-resistant prostate cancer, bone-seeking radionuclide therapy, irradiation for macular degeneration, and translational research in radiation and prostate cancer, and he has published widely in these areas. Es ist keine Anmeldung notwendig. Die Teilnahme ist kostenlos. Mit freundlicher Unterstützung von Bayer (Schweiz) AG Organisation: Cancer Center Zürich, UniversitätsSpital Zürich, Prof. Dr. Rolf Stahel, Leiter Cancer Center Zürich, PD Dr. Irene A. Burger, Klinik für Nuklearmedizin, Rämistrasse 100, 8091 Zürich www.fortbildung.usz.ch | [email protected] | +41 44 255 30 35